Meningeal carcinomatosis as the initial manifestation of lymphoma.
DOI:
https://doi.org/10.19230/jonnpr.4820Abstract
Introduction: Leptomeningeal carcinomatosis (LC) is diagnosed in 4-15% of cancer patients, and most cases (70%) are in the advanced phase of the disease. In only 5-10% of patients with LC, it is the initial manifestation of cancer.
Case report: We present a case of a 46-year-old man with leptomeningeal carcinomatosis as the first manifestation of type B high-grade lymphoma. Cerebrospinal fluid (CSF) showed pleocytosis with a predominance of mononuclear cells, hyperproteinorrhachia, and glucose consumption. CSF cytology was negative for malignant cells in two samples. Magnetic resonance imaging and CSF flow cytometry gave the diagnosis.
Discussion: LC is a diagnostic challenge. Differential diagnosis arises with infectious processes (tuberculosis) and autoimmune diseases. In cerebrospinal fluid, flow cytometry (FCM) has a higher sensitivity than cytology for the diagnosis of LC.
Downloads
References
Schiff D, Arrillaga I, Wen PY. Cancer neurology in clinical practice: neurological complications of cancer and its treatment. 2018. Springer.
Jaffe ES, Barr PM, Smith SM. Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice. Am Soc Clin Oncol Educ Book. 2017;37:535-546. https://doi.org/10.1200/EDBK_175437.
Meng X, Yu J, Fan Q, Li L, Li W, Song Z, et al. Characteristics and outcomes of non-Hodgkin’s lymphoma patients with leptomeningeal metastases. Int J Clin Oncol. 2018;23(4):783-9. https://doi.org/10.1007/s10147-018-1268-5.
Nayak L, Batchelor TT. How I treat neurologic complications in patients with lymphoid cancer. Blood. 2022;139(10):1469-78. https://doi.org/10.1182/blood.2019003690
Nolan CP, Abrey LE. Leptomeningeal metastases from leukemias and lymphomas. Cancer Treat Res. 2005;125:53-69. https://doi.org/10.1007/0-387-24199-x_4.
van Oostenbrugge RJ, Twijnstra A. Presenting features and value of diagnostic procedures in leptomeningeal metastases. Neurology. 1999;53(2):382-5. https://doi.org/10.1212/wnl.53.2.382.
Kaplan JG, DeSouza TG, Farkash A, Shafran B, Pack D, Rehman F, et al. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol. 1990;9(3):225-9.https://doi.org/10.1007/BF02341153
Hegde U, Filie A, Little RF, Janik JE, Grant N, Steinberg SM, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood. 2005;105(2):496-5. https://doi.org/10.1182/blood-2004-05-1982.
Song J, Kim SH, Jung YR, Choe J, Kang CI, Min JH. 10-Year Retrospective Review of the Etiologies for Meningitis With Elevated Adenosine Deaminase in Cerebrospinal Fluid: Etiologies Other Than TB. Front Cell Infect Microbiol. 2022;12:858724. https://doi.org/10.3389/fcimb.2022.858724.
Downloads
Published
Issue
Section
License
All accepted originals remain the property of JONNPR. In the event of publication, the authors exclusively transfer their rights of reproduction, distribution, translation and public communication (by any sound, audiovisual or electronic medium or format) of their work. To do so, the authors shall sign a letter transferring these rights when sending the paper via the online manuscript management system.
The articles published in the journal are freely used under the terms of the Creative Commons BY NC SA license, therefore.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
